Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/146483
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Puñet Ortiz, Joan | - |
dc.contributor.author | Sáez Moya, Manuel | - |
dc.contributor.author | Cuenca, Marta | - |
dc.contributor.author | Caleiras, Eduardo | - |
dc.contributor.author | Lázaro, Adriana | - |
dc.contributor.author | Engel Rocamora, Pablo | - |
dc.date.accessioned | 2019-12-11T13:46:59Z | - |
dc.date.available | 2019-12-11T13:46:59Z | - |
dc.date.issued | 2018-11-16 | - |
dc.identifier.issn | 1664-3224 | - |
dc.identifier.uri | http://hdl.handle.net/2445/146483 | - |
dc.description.abstract | Sjögren's Syndrome (SjS) is a common chronic autoimmune disease characterized by the B cell hyperactivation, lymphocyte infiltration, and tissue damage of exocrine glands. It can also present life-threatening extraglandular manifestations, such as pulmonary and hepatic involvement, renal inflammation and marginal zone (MZ) B cell lymphoma. Several biologic agents have been tested in SjS but none has shown significant efficacy. Here, we report the effects of Ly9 (CD229) antibody targeting, a cell surface molecule that belongs to the SLAM family of immunomodulatory receptors, using NOD.H-2h4 mice as a model of SjS-like disease. Female mice were treated with anti-Ly9 antibody or isotype control at week 24, when all mice present SjS related autoantibodies, salivary gland infiltrates, and marginal zone (MZ) B cell pool enlargement. Antibody injection depleted key lymphocyte subsets involved in SjS pathology such as MZ, B1, and germinal center B cells in spleen and draining lymph nodes without inducing a general immunosuppression. Importantly, mice receiving anti-Ly9 mAb showed a reduced lymphocyte infiltrate within salivary glands. This reduction may be, in part, explained by the down-regulation of L-selectin and alfa4/beta7 integrin induced by the anti-Ly9 antibody. Furthermore, levels of anti-nuclear autoantibodies were reduced after anti-Ly9 treatment. These data indicate that Ly9 is a potential therapeutic target for the treatment of SjS. | - |
dc.format.extent | 14 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Frontiers Media | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2018.02661 | - |
dc.relation.ispartof | Frontiers in Immunology, 2018, vol. 9, p. 2661 | - |
dc.relation.uri | https://doi.org/10.3389/fimmu.2018.02661 | - |
dc.rights | cc-by (c) Puñet Ortiz, Joan et al., 2018 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Biomedicina) | - |
dc.subject.classification | Autoimmunitat | - |
dc.subject.classification | Síndrome de Sjögren | - |
dc.subject.classification | Models animals en la investigació | - |
dc.subject.other | Autoimmunity | - |
dc.subject.other | Sjogren's syndrome | - |
dc.subject.other | Animal models in research | - |
dc.title | Ly9 (CD229) antibody targeting depletes marginal zone and germinal center B cells in lymphoid tissues and reduces salivary gland inflammation in a mouse model of Sjögren's Syndrome | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 686408 | - |
dc.date.updated | 2019-12-11T13:47:00Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 30519241 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Biomedicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
686408.pdf | 5.17 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License